The critical role of the PD-1 pathway as a deterrent to anticancer immunity has now been validated in clinical studies using anti-PD-1 monoclonal antibody, and this will likely be a paradigm shift in HCC [36]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.